Forsta AP Fonden grew its position in Pfizer Inc. (NYSE:PFE) by 379.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,600 shares of the biopharmaceutical company’s stock after buying an additional 110,500 shares during the period. Forsta AP Fonden’s holdings in Pfizer were worth $6,152,000 as of its most recent SEC filing.
Several other institutional investors have also recently bought and sold shares of PFE. Charles Schwab Investment Advisory Inc. acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $286,229,000. Dimensional Fund Advisors LP lifted its holdings in shares of Pfizer by 15.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock worth $1,967,651,000 after acquiring an additional 7,059,171 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Pfizer by 3,845.7% in the 3rd quarter. Bessemer Group Inc. now owns 6,366,640 shares of the biopharmaceutical company’s stock worth $280,580,000 after acquiring an additional 6,205,282 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Pfizer by 20.7% in the 2nd quarter. Macquarie Group Ltd. now owns 25,340,162 shares of the biopharmaceutical company’s stock worth $919,341,000 after acquiring an additional 4,344,595 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its holdings in shares of Pfizer by 110.5% in the 2nd quarter. Federated Investors Inc. PA now owns 6,263,587 shares of the biopharmaceutical company’s stock worth $227,243,000 after acquiring an additional 3,287,377 shares during the last quarter. 70.61% of the stock is owned by institutional investors and hedge funds.
In other Pfizer news, EVP Douglas M. Lankler sold 38,800 shares of the stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $41.19, for a total value of $1,598,172.00. Following the sale, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 5,000 shares of the stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $42.75, for a total transaction of $213,750.00. Following the completion of the sale, the executive vice president now directly owns 83,592 shares in the company, valued at $3,573,558. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Shares of NYSE:PFE opened at $42.23 on Monday. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $46.47. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $251.39 billion, a price-to-earnings ratio of 14.08, a PEG ratio of 2.42 and a beta of 0.77.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. The company had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. During the same period in the prior year, the firm posted $0.62 EPS. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.86 earnings per share for the current year.
Pfizer announced that its Board of Directors has approved a share buyback plan on Friday, December 14th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase up to 3.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, February 1st will be given a $0.36 dividend. The ex-dividend date of this dividend is Thursday, January 31st. This is an increase from Pfizer’s previous quarterly dividend of $0.34. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.41%. Pfizer’s dividend payout ratio is currently 48.00%.
Several equities analysts have recently commented on PFE shares. JPMorgan Chase & Co. restated a “buy” rating on shares of Pfizer in a report on Tuesday, October 30th. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 target price on shares of Pfizer in a report on Wednesday, October 17th. Atlantic Securities reiterated a “buy” rating and set a $54.00 target price on shares of Pfizer in a report on Tuesday, November 27th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Thursday, January 31st. Finally, Societe Generale set a $43.00 target price on shares of Pfizer and gave the stock a “hold” rating in a report on Thursday, November 1st. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average target price of $44.68.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Article: Are all No-Load Funds Equal?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.